We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+9.97%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$642M
AUM Growth
+$30M
Cap. Flow
-$8.58M
Cap. Flow %
-1.34%
Top 10 Hldgs %
52.02%
Holding
62
New
16
Increased
10
Reduced
19
Closed
11

Top Buys

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$35.8M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.2M
3
KALA icon
KALA BIO
KALA
+$10.4M
4
AMAG
AMAG Pharmaceuticals
AMAG
+$10.1M
5
NUVA
NuVasive, Inc.
NUVA
+$8.93M

Top Sells

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$30.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$27.9M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$21.6M
4
ENDP
Endo International plc
ENDP
+$18.9M
5
ANGO icon
AngioDynamics
ANGO
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 87.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
1
DELISTED
La Jolla Pharmaceutical Company
LJPC
$49.3M 7.69%
1,656,720
+626,854
+61% +$20.2M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$44.3M 6.91%
1,443,948
-1,003,798
-41% -$27.9M
HRTX icon
3
Heron Therapeutics
HRTX
$88.7M
$43.6M 6.8%
1,581,416
-447,102
-22% -$10.1M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$36.4M 5.67%
2,564,175
-453,846
-15% -$6.7M
CORI
5
DELISTED
Corium International, Inc.
CORI
$35.8M 5.58%
3,119,645
-312,681
-9% -$3.77M
ADMS
6
DELISTED
Adamas Pharmaceuticals
ADMS
$27.1M 4.23%
+1,135,203
New +$35.8M
TVTX icon
7
Travere Therapeutics
TVTX
$5.17B
$26.3M 4.11%
1,178,226
-463,642
-28% -$11M
SBBP
8
DELISTED
Strongbridge Biopharma plc.
SBBP
$24.7M 3.85%
2,793,752
-392,943
-12% -$2.94M
SCTL
9
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$24.6M 3.84%
2,493,168
-223,000
-8% -$1.87M
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
$21.5M 3.35%
537,380
+80,300
+18% +$3.18M
GWPH
11
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$19.7M 3.07%
175,030
+52,100
+42% +$6.55M
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$19.1M 2.98%
2,624,663
+32,942
+1% +$290K
PETX
13
DELISTED
Aratana Therapeutics, Inc.
PETX
$18.9M 2.95%
4,294,426
– –
IART icon
14
Integra LifeSciences
IART
$1.48B
$16.5M 2.57%
298,424
-32,176
-10% -$1.69M
CPRX
15
DELISTED
Catalyst Pharmaceutical
CPRX
$16.3M 2.54%
6,812,764
-284,536
-4% -$946K
ANGO icon
16
AngioDynamics
ANGO
$555M
$15.7M 2.45%
911,707
-820,654
-47% -$13.7M
IOVA icon
17
Iovance Biotherapeutics
IOVA
$2.15B
$15.4M 2.4%
912,987
-1,427,624
-61% -$21.6M
NUVA
18
DELISTED
NuVasive, Inc.
NUVA
$13.5M 2.1%
258,292
+176,192
+215% +$8.93M
AMAG
19
DELISTED
AMAG Pharmaceuticals
AMAG
$12.1M 1.88%
+598,800
New +$10.1M
KALA icon
20
KALA BIO
KALA
$14M
$10.8M 1.68%
+273
New +$10.4M
ATRS
21
DELISTED
Antares Pharma, Inc.
ATRS
$10.3M 1.6%
4,673,247
+137,600
+3% +$310K
BDSI
22
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$9.63M 1.5%
4,278,819
-355,300
-8% -$832K
GKOS icon
23
Glaukos
GKOS
$9.15B
$9.06M 1.41%
+293,900
New +$8.9M
ANAB icon
24
AnaptysBio
ANAB
$1.63B
$8.24M 1.28%
+79,200
New +$8.93M
CI icon
25
Cigna
CI
$75.2B
$7.15M 1.11%
+42,600
New +$8.28M
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Broadfin Capital held 62 positions worth $642M, up 4.9% from $612M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital's Q1 2018 filing shows 16 new, 10 increased, 19 reduced and 11 closed positions. Its largest new stake was Adamas Pharmaceuticals: 1,135,203 shares worth $27.1M. The largest sale was Ignyta, Inc., an estimated $30.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 92% a quarter earlier.

  • Broadfin Capital's largest Q1 2018 buy was Adamas Pharmaceuticals: 1,135,203 shares worth $27.1M.
  • Broadfin Capital added most to La Jolla Pharmaceutical Company in Q1 2018, an estimated $20.2M increase.
  • Broadfin Capital's biggest Q1 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $27.9M.
  • Broadfin Capital fully exited Ignyta, Inc. in Q1 2018, selling an estimated $30.7M.
  • Broadfin Capital's ten largest holdings make up 52% of its $642M portfolio in Q1 2018.
  • Broadfin Capital opened 16 new positions and closed 11 in Q1 2018.
  • Broadfin Capital's portfolio value rose 4.9% quarter-over-quarter to $642M.

Based on Broadfin Capital's 13F filing for Q1 2018, filed 14 May 2018.